Unknown PHASE2 INTERVENTIONAL 1-arm NCT04370405

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

A Phase 2, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of YY-20394 in Subjects With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Conditions Lymphoma, Follicular

Interventions YY-20394

Updated 6 times since 2020 Last updated: May 7, 2020 Started: Apr 29, 2019 Primary completion: Nov 30, 2020 Completion: Feb 22, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04370405, this PHASE2 trial focuses on Lymphoma, Follicular and remains ongoing. Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd., it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jun 2022 [monthly]

Recruiting PHASE2
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

May 2020 — Jun 2020 [monthly]

Recruiting PHASE2

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai YingLi Pharmaceutical Co. Ltd.

Data source: Shanghai YingLi Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China